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1. Introduction
Sunitinib malate (Sutent, Pfizer inc., New York, NY) is an orally administered, multitargeted
inhibitor of tyrosine kinases, including vascular endothelial growth factor (VEGF) receptor,
platelet-derived growth factor (PDGF) receptor, stem cell factor receptor (KIT), fms-like ty‐
rosine kinase (FLT) -3, CSF-1R, and RET. Since the introduction of sunitinib for patients with
advanced renal tumor [1], significant objective responses of sunitnib have been revealed
[2-6]. In a randomized, multicenter, phase III trial enrolled 750 patients with previously-un‐
treated metastatic renal tumor to receive either sunitinib or interferon (IFN) -α, sunitinib
was superior to IFN-α in the objective response rate (47% vs 12%), progression-free survival
time (11.0 vs 5.0 months), and overall survival time (26.4 vs 21.8 months) [3, 4]. Also in a Jap‐
anese, multicenter, phase II trial enrolled 51 patients with first-line and pretreated metastatic
clear-cell renal tumor to recieve sinitinib, significant responses of sunitinib have been report‐
ed that objective response rate was 52.9%, the median progression-free survival time was
12.2 and 10.6 months, and the median overall survival time was 33.1 and 32.5 months in
first-line and pretreated patients, respectively [5, 6]. Sunitinib is approved worldwide for
first-line treatment of advanced clear-cell renal tumor. However, approximately half of pa‐
tients with advanced renal tumor do not see clinical benefits from sunitinib treatment. A
prognostic marker is needed for selecting patients who will benefit most from sunitinib.
It has been advocated that the necessity of determining molecular and clinical biomarkers
that may predict efficacy of sunitinib. The identification of biomarkers to predict response is
urgently needed. This chapter provides a brief overview of the signaling pathways of renal
tumors and introduces biomarkers to predict response to sunitinib of clinical variables.
© 2013 Fujita et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Signaling pathways in renal tumors
Renal tumors originates from the tubular structures of the kidney and is calssified into four
major histological cell types. Clear-cell renal tumor is the most common type, accounting for
approximately 75% of all renal tumors. Other types are followed by papillary renal tumor
(approximately 15%), chromophobe renal tumor (approximately 5%), and renal oncocytoma
(approximately 5%) [7].
The most important molecular disorder in renal tumors involves the von Hippel-Lindau
(VHL) tumor suppressor gene, which is responsible for clear-cell renal tumors. The protein
production of the VHL gene, which is located on chromosome 3p25, prevents angiogenesis
and suppresses tumors [7]. Inactivating the phosphorylated VHL protein activates hypoxia-
inducible factor (HIF) and the induction of VEGF in clear-cell renal tumors. Mesenchymal-
epithelial transition factor (MET) and fumarate hydratase (FH) are responsible for papillary
renal tumors. While chromophobe renal tumors, Birt-Hogg-Dube (BHD) tumor suppresor
gene is mutated [8]. The inherited renal tumor genes VHL, MET, FH, folliculin, succinate dehy‐
drogenase, tuberous sclerosis complex (TSC) 1, and TSC2 are all involved in metabolic path‐
ways related to oxygen, iron, energy, and nutrient sensing [9].
Alterations in proto-oncogenes and tumor suppressor genes leads to dysregulated signal
transduction that underlies the abnormal growth and proliferation of cancer cells. Signaling
proteins that are centrally located in important cancer-associated signaling networks can
serve as therapeutic targets [10].
2.1. Angiogenetic signaling pathways
Renal tumors are frequnently characterized by hypoxic conditions. Hypoxia and compensa‐
tory hyperactivation of angiogenesis are thought to be particularly important in renal tu‐
mors, given the highly vascularized nature and the specific association of mutation in VHL,
a critical regulator of the hypoxic response. Hypoxic signaling is mediated by HIF. Increased
expression of HIF target genes is implicated in promoting cancer, inducing both changes
within the tumor and changes in the growth of adjacent endothelial cells to promote blood
vessel growth. The expression level of VEGF in renal tumors is known to strongly correlate
with microvessel density [10].
2.2. PI3K/AKT/mTOR pathway
Mammalian target of rapamycin (mTOR) and protein kinase B (AKT) are key oncogenic
process including cell proliferation, survival, and angiogenesis. PI3K promotes the genera‐
tion of phosphatidylinositol-3, 4, 5-triphosphate. Signaling from VEGF and PDGF through
AKT activates mTOR. Components of this PI3K/AKT/mTOR pathway are constitutively acti‐
vated in renal tumors compared to normal renal tissues [11].
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2.3. HGF/MET pathway
Changes in expression and activity of hepatocyte growth factor (HGF) and its receptor c-
MET have been associated with renal tumors. HGF binding to MET leads to phosphory‐
lation of two tyrosine residues at the C-terminus of MET, which leads to the recruitment
of adapter proteins and activation of PI3K/AKT pathway to promote renal tumor growth
and metastasis [12].
3. Biomarkers of response to sunitinib in renal tumors
3.1. Prognostic model
In the cytokine era, Motzer et al. [13] reported Memorial Sloan-Kettering Cancer Center
(MSKCC) risk classification, which is based on data from 463 patients with advanced renal
tumor who were treated with IFN-α cytokine therapy as first-line systemic therapy. The
MSKCC risk classification extracted five variable risk factors for short survival: low Karnof‐
sky performance status (PS) (< 80%), high lactate dehydrogenase (> 1.5 times the upper limit
of normal), low serum hemoglobin, high corrected serum calcium (> 10 mg/dL), and time
from initial renal tumor diagnosis to IFN-α therapy of less than one year. Each patient was
assigned to one of three risk groups: those with zero risk factors (favorable risk), those with
one or two risk factors (intermediate risk), and those with three or more risk factors (poor
risk). The median time to death was 30, 14, and 5 months in the favorable, intermediate, and
poor-risk groups, respectively [13]. These five risk criteria are now most frequently used
prognostic model for patients with advanced renal tumor.
In the era of targeted therapy, Heng et al. [14] reported a new prognostic model that added
platelet and neutrophil counts to the MSKCC model from a large multicenter study of 645
patients with metastatic renal tumor who were treated with targeted therapy. This study in‐
cluded three groups of patients: 396 patients treated with sunitinib, 200 patients treated with
sorafenib, and 49 patients treated with bevacizumab. Four of the five adverse prognostic fac‐
tors according to the MSKCC risk classification−low hemoglobin, high corrected serum cal‐
cium, low Karnofsky PS, and time from the initial renal tumor diagnosis to the start of
treatment of less than one year−emerged as independent predictors of poor survival. Addi‐
tionally, platelets greater than the upper limit of normal range, and neutrophils greater than
the upper limit of normal range, emerged as independent adverse prognostic factors.
MSKCC model with the addition of platelet and neutrophil counts can be incorporated into
patient care of targeted therapies [14].
3.2. C-reactive protein
C-reactive protein (CRP), a non-specific inflammatory acute-phase protein, is a representa‐
tive marker of systemic inflammatory response. CRP levels correlate with the production of
proinflammatory cytokines, such as interleukin (IL) -6 [15], and with tumor progression [16,
17]. It has been recognized as an important prognostic marker in the cytokine era. Atzpo‐
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dien et al. [16] reported data from 425 patients who received cytokine-based home therapy.
On multivariate analysis, elevated CRP (≥ 1.1 mg/dL) was a poor prognostic factor, and Kaplan-
Meier analysis demonstrated that patients with elevated CRP had significantly worse over‐
all survival [16]. Casamassima et al. [17] reported that normal CRP (≤ 0.8 mg/dL) was the most
independent prognostic factor for 110 patients treated with IL-2-based immunotherapy. Ram‐
sey et al. [18] investigated the Glasgow Prognostic Score, which is based on a combination of
hypoalbuminemia and elevated CRP (> 1.0 mg/dL). They found that CRP was independent‐
ly associated with cancer-specific survival in 119 patients receiving immunotherapy [18]. Saito
et al. [19] described that CRP kinetics have an impact on survival in patients with metastatic
renal tumor treated with immunotherapy and/or metastasectomy. A decrease of CRP level
during treatment predicts better prognosis in patients with metastatic renal tumor, and pro‐
longed normalized CRP period is associated with prolonged survival [19].
Variable Univariate Multivariate
Odds Ratio
(95% Confidence Interval) P-value
Odds Ratio
(95% Confidence Interval) P-value
Pretreatment
Age 0.988 (0.920−1.061) 0.7410
Gender 0.573 (0.139−2.355) 0.4384
ECOG PS0 4.200 (0.884−19.947) 0.0598
MSKCC non-poor 0.150 (0.026−0.864) 0.0206 0.632 (0.058−6.850) 0.7042
First-line 0.879 (0.238−3.249) 0.8468
Normal CRP 17.600 (1.961−157.970) 0.0011 13.525 (1.111−164.602) 0.0163
Adverse events
Hypertension 3.667 (0.954−14.094) 0.0523
HFS 6.500 (1.537−27.490) 0.0069 2.272 (0.324−15.930) 0.4104
Stomatitis 3.200 (0.826−12.404) 0.0844
Diarrhea 1.375 (0.368−5.136) 0.6347
Altered taste 8.250 (1.498−45.436) 0.0064 4.422 (0.533−36.655) 0.1517
Fatigue 5.133 (1.131−23.303) 0.0238 1.572 (0.192−12.841) 0.6740
Leukopenia 8.333 (0.867−80.130) 0.0337 5.436 (0.190−155.246) 0.2717
Anemia 1.771 (0.392−8.003) 0.4559
Thrombocytopenia 758.701 (0.000) 0.0670
Increased creatinine 2.182 (0.566−8.415) 0.2505
TSH abnormalities 2.812 (0.734−10.774) 0.1255
Table 1. Univariate and multivariate logistic regression analyses for selected variables
In the targeted therapy era, Fujita et al. [20] recently reported that CRP is an independent
prognostic indicator for patients with advanced renal tumor treated with sunitinib. A total of
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41 consecutive patients between December 2008 and August 2011 were enrolled in this study.
All patients had histologically proven clear-cell renal tumor. Non-tumor variables which were
selected from pretreatment characteristics and treatment-related adverse events were ana‐
lyzed on univariate and multivariate logistic regression analysis. Pretreatment characteris‐
tics were age, gender, Eastern Cooperative Oncology Group (ECOG) PS 0, MSKCC non-
poor (favorable and intermediate)  risk,  first-line treatment,  and normal CRP. Treatment-
related adverse events were hypertension, hand-foot skin reaction (HFS), stomatitis, diarrhea,
altered taste, fatigue, leukopenia, anemia, thrombocytopenia, increased creatinine, and thyroid-
stimulating hormone (TSH) abnormalities. On univariate analyses among pretreatment char‐
acteristics,  MSKCC non-poor risk classification and normal  CRP level  were significantly
correlated with response to treatment (P = 0.0206 and 0.0011, respectively). Among adverse
events,  HFS,  altered taste,  fatigue,  and leukopenia were significantly corralated with re‐
sponse to treatment (P = 0.0069, 0.0064, 0.0238, and 0.0337, respectively). Variable values in the
multivariate analysis included MSKCC non-poor risk classification, normal CRP, HFS, al‐
tered taste, fatigue, and leukopenia. After adjusting for differences in these variables, nor‐
mal CRP was independently associated with response to treatment (P = 0.0163).
Patients were grouped into two cohorts: those with normal CRP levels (≤ 0.30 mg/dL) and
those with elevated CRP levels (> 0.30 mg/dL), according to the normal values provided by
the manufacturer. The cohort with normal CRP comprised 10 males and 3 females (total 13
patients; 31.7%) with a median age of 63 years (range 46−77 years). The elevated CRP cohort
comprised 20 males and 8 females (total 28 patients; 68.3%) with a median age of 64 years
(range 36−80 years). MSKCC risk classification was favorable for 15.4% of the normal CRP
cohort and intermediate for 86.4%. In contrast, in the elevated CRP cohort, MSKCC risk clas‐
sification was favorable for 21.4%, intermediate for 46.4%, and poor for 32.2%. The differ‐
ence in risk classification between the two groups was statistically significant (P = 0.0377).
There were no statistically significant differences in any other pretreatment variables and tu‐
mor characteristics. The rate of partial response plus stable disease to treatment was 84.6%
for the normal CRP cohort and 35.7% for the elevated CRP cohort. The higher response rate
observed in the normal CRP cohort was statistically significant (P = 0.0022).
Normal CRP
(≤ 0.30 mg/dL)
Elevated CRP
(> 0.30 mg/dL) P-value
13 (31.7%) 28 (68.3%)
Gender (n (%)) 0.7118
Male 10 (76.9) 20 (71.4)
Female 3 (23.1) 8 (28.6)
Age (years) 0.5953
Median 63 64
Range 46−77 36−80
Mean ± standard deviation 64.8 ± 9.0 63.2 ± 9.1
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Normal CRP
(≤ 0.30 mg/dL)
Elevated CRP
(> 0.30 mg/dL) P-value
ECOG PS (n (%)) 0.0595
0 12 (92.3) 18 (64.3)
≥ 1 1 (7.7) 10 (35.7)
MSKCC risk classification (n (%)) 0.0377
Favorable 2 (15.4) 6 (21.4)
Intermediate 11 (84.6) 13 (46.4)
Poor 0 (0) 9 (32.2)
Prior nephrectomy (n (%)) 0.2767
Yes 12 (92.3) 22 (78.6)
No 1 (7.7) 6 (21.4)
T stage (n (%)) 0.8187
T1 or T2 6 (46.2) 14 (50.0)
≥ T3 7 (53.8) 14 (50.0)
Grade (n (%)) 0.6628
1 or 2 9 (69.2) 17 (60.7)
3 3 (23.1) 8 (28.6)
Prior immunotherapy (n) 0.2482
IFN-α 9 14
IL-2 and IFN-α 3 6
Prior targeted therapy (n) 0.8651
Sorafenib 5 10
Metastatic sites (n)
Lung 12 21
Bone 2 12
Lymph nodes 3 7
Brain 1 3
Pancreas − 4
Adrenal − 4
Skin − 3
Kidney − 2
Local − 2
Liver − 2
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Normal CRP
(≤ 0.30 mg/dL)
Elevated CRP
(> 0.30 mg/dL) P-value
Prostate 1 −
No. metastatic sites (n (%)) 0.1929
1 6 (46.1) 8 (28.6)
≥ 2 6 (46.1) 20 (71.4)
Treatment (n (%)) 0.2122
First-line 3 (23.1) 13 (46.4)
Second-line 6 (46.1) 6 (21.4)
Third-line 4 (30.8) 9 (32.2)
Responses (n (%)) 0.0022
Partial response plus stable disease 11 (84.6) 10 (35.7)
Table 2. Patient characteristics grouped by CRP level
The median progression-free survival time for the elevated CRP cohort was 6.0 months. In
contrast, the median progression-free survival time for the normal CRP cohort was signifi‐
cantly longer, at 19.0 months (log-rank P = 0.0361).
Figure 1. Kaplan-Meier progression-free survival for patients grouped by CRP level
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CRP is a significant independent prognostic indicator for patients with advanced renal tu‐
mor treated with sunitinib. Pretreatment CRP level could be a useful biomarker for response
to sunitinib treatment [20].
3.3. Selected adverse events
Sunitinib has been related a variety of adverse events, key notable clinical adverse events
included diarrhea (61%), fatigue (54%), hypertension (30%), stomatitis (30%), HFS (29%),
and asthenia (20%) [4]. Laboratory abnormalities also found that included leukopenia (78%),
anemia (79%), increased creatinine (70%), and thrombocytopenia (68%) [4]. If adverse events
depends on the degree of systemic exposure to sunitinib, on which clinical efficacy also de‐
pends, adverse events might be potential predictors of sunitinib efficacy [21]. Several au‐
thors have described the correlation between sunitinib responses and selected treatment-
related adverse events.
3.3.1. Hypertension
Hypertension is commonly associated with targeted therapy. It develops when VEGF stimu‐
lates production of nitric oxide and prostacyclins in vascular endothelial cells [22, 23], vaso‐
dilatory mechanisms become inhibited, and peripheral vascular resistance increases, leading
to increased blood pressure.
Rini et al. [24] demonstrated that sunitinib-associated hypertension is associated with im‐
proved clinical outcomes without clinically significant increases in hypertension-associated
adverse events. This analysis included large pooled data from four clinical trilas of 4915 pa‐
tients with metastatic renal tumor who were treated with sunitinib. Sunitinib-induced hy‐
pertension had significantly better outcomes than those without treatment-induced
hypertension in the objective response rate (54.8% vs 8.7%), the median progression-free sur‐
vival time (12.5 vs 2.5 months), and the median overall survival time (30.9 vs 7.2 months, P<
0.001 for all) [24].
Bono et al. [25] reported that sunitinib-induced hypertension was associated with frequent
tumor response (P = 0.001), significantly longer disease progression time (P = 0.0003), and
overall survival time (P = 0.001). On multivariate analysis including the variables of pretreat‐
ment hemoglobin, pretreatment calcium level, PS, time from diagnosis to onset of metasta‐
sis, and treatment-related hypertension, hypertension was an independent predictor of
progression-free survival (P = 0.0030) [25].
Szmit et al. [26] reported that patients who developed hypertension related to sunitinib
treatment experienced significantly longer progression-free survival time and overall sur‐
vival time compared to those who did not hypertension (P< 0.00001). Patients treated with at
least 3 antihypertensive agents experienced significantly longer progression-free survival
time (P = 0.00002) and overall survival time (P = 0.00001) compared either with patients who
received one or two medications or with patients who received no medications [26].
Rixe et al. [27] reported that appearance or worsening hypertension was found to be the sin‐
gle independent predictor of a better clinical response to sunitinib on multivariate analysis
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using logistic regression model (P = 0.009). Furthermore, grade 3 hypertension was correlat‐
ed with a better outcome (P = 0.03). The appearance of hypertension, particularly grade 3,
was associated with higher treatment response to sunitinib in metastatic renal tumors. Early
and intensive antihypertensive therapy with the goal of maintaining the sunitinib use may
improve response rate in those patients [27].
Overall, hypertension related to sunitinib was a positive predictive factor associated with
significantly better objective response rate, longer progression-free survival and overall sur‐
vival in patients with metastatic renal tumor treated with sunitinib.
3.3.2. Hypothyroidism
Treatment-related hypothyroidism has been reported a useful predictor of progression-free
survival for metastatic renal tumors undergoing treatment with sunitinib [28]. In the 52 patients
with metastatic renal tumor treated with sunitinib, 13 patients (25.0%) developed hypothyr‐
oidism during treatment. Subclinical hypothyroidism was defined as serum TSH above the
upper limit of normal, with total triiodothyronine (T3) and thyroxine (T4) within normal limits.
Clinical hypothyroidism was defined as low serum T3 and T4 together with elevated TSH.
Hypothyroidism was associated with a longer progression-free survival time (P  = 0.032).
Hormone replacement with 1-thyroxine did not have an influence on survival [28].
3.4. Others
Han et al. [29] reported the initial tumor enhancement on contrast-enhanced computed to‐
mography (CT) could be useful as a clinical predictor during targeted therapy in 198 meta‐
static lesions of 46 patients. On multivariate analyses, tumor enhancement and enhancement
pattern were associated with objective responses (P = 0.003 and 0.028, respectively). Addi‐
tionally, tumor enhancement was associated with tumor size reduction (P = 0.004). On Cox
proportional hazards models, only tumor enhancement was associated significantly with
the time to size reduction and progression-free survival time (P = 0.03 and 0.015, respective‐
ly). Tumor enhancement on contrast-enhanced CT was associated with tumor size reduc‐
tion, time to response, and time to progression of individual metastases in patients with
metastatic renal tumor who received targeted therapy [29].
Kayani et al [30] revealed prognostic significance of 18F-fluorodeoxyglucose-positron emis‐
sion tomography (FDG-PET)/CT as a biomarker of response to sunitinib. A total of 44 pa‐
tients with newly diagnosed untreated metastatic renal tumor were enrolled in this study.
18F-FDG-PET/CT scans were conducted before, after 4 weeks, and after 16 weeks of sunitinib
given. On multivariate analysis, a high SUVmax and an increased number of PET-positive le‐
sions correlated with shorter overall survival. The early metabolic responses are associated
with a pharmacodynamic effect of drug and it is not until later identification with acquired
resistance occurs [30].
Yuasa et al. [31] reported that initial tumor size is inversely associated with the tumor reduc‐
tion rate of individual metastatic sites and primary tumors in patients with metastatic renal
tumor who underwent targeted therapy. A data from 139 metastatic and 16 primary lesions
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treated with targeted agents were analyzed. Both univariate and multivariate linear regres‐
sion analyses revealed that only the initial tumor size was associated with the rate of reduc‐
tion in individual tumors (P< 0.001) [31].
Abel et al. [32] reported that early 10% decrease in tumor diameter of the primary tumor
was predictive of improved overall survival in patients with metastatic renal tumor treated
with sunitinib. In 75 consecutive treatment-naive patients, median overall survival time for
patients without minor primary tumor response, with minor primary tumor response after
60 days, and with early minor primary tumor response was 10.3, 16.5, and 30.2 months, re‐
spectively. On multivariate analysis, early minor response was an independent predictor of
improved overall survival (P = 0.031) [32].
High visceral fat area could be a predictive biomarker from shorter survival in patients giv‐
en first-line antiangiogenic agents including sunitinib for metastatic renal tumors [33]. In 113
study population, 46 patients received sunitinib as first-line therapy. Visceral fat area was
measured retrospectively on the available CT scans performed before sunitinib initiation at
the level of the umbilicus with the patient in the supine position. ImageJ software was used
to measure pixels with densities in the -190 Hounsfield units to -30 Hounsfield units range
to delineate the visceral compartment and to compute the cross-sectional area of each in cm2.
On multivariate analysis, high visceral fat area was independently associated with shorter
time to progression and overall survival. Visceral fat area measured before starting first-line
targeted therapy is likely to be a simple predictive biomarker in patients with metastatic re‐
nal tumor [33].
Finally, hyponatremia seem to represent significant predictive factor for cancer-specific sur‐
vival in metastatic renal tumors treated with targeted therapy as first-line therapy [34]. A
total of 87 patients treated with targeted therapy including sunitinib, severe (≤ 134 mEq/L)
and mild (135-137 mEq/L) hyponatremia was shown to be significantly associated with can‐
cer-specific survival time (P = 0.001 and 0.013, respectively). In 38 patients treated wth suni‐
tinib, 4 patients (10.5%) developed severe hyponatremia and 8 patients (21.1%) developed
mild hyponatremia. Hyponatremia could be easily and readily determined and might be an
important prognostic factor [34].
4. Conclusions
Candidate biomarkers to predict response to sunitinib have been shown. Among clinical factors,
CRP is a significant independent prognostic indicator for sunitinib. Severe adverse events,
hypertension and hypothyroidism also recognized as biomarkers of favorable efficacy. Addi‐
tionally, tumor enhancement, SUVmax on FDG/PET-CT, tumor size, visceral fat area and hypo‐
natremia have been revealed clinical significance of sunitinib responses. Although further
investigation will be required, these biomarkers can be utilized to measure therapeutic re‐
sponse and design treatment strategies for advanced renal tumors treated with sunitinib.
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